GSK buys out Novartis in $13bn consumer healthcare deal
27-03-2018
kadmy / iStockphoto.com
Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea (aflibercept) and Zaltrap (ziv-aflibercept).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Novartis, Regeneron, eye disorder, retina disorder, Lucentis, Eylea, Zaltrap, District Court for the Southern District of New York, patented medical techno
